Becker's Hospital Review has included VCU Massey Cancer Center in its list of "100 Hospitals and Health Systems With Great Oncology Programs." According to its Web site, "These hospitals are on the cutting edge of cancer treatment, prevention and research, and the Becker's Hospital Review editorial team selected them based on clinical accolades, quality care and contributions to the field of oncology."
Best Doctors Inc. has named 12 physicians from the Virginia Commonwealth University Massey Cancer Center to the 2013 list of Best Doctors in America®. These physicians are among 5 percent of the doctors in America selected by their peers of more than 45,000 physicians. Doctors are evaluated based on their credentials, clinical activity and accessibility to existing or new patients.
The “Life and Love After Cancer” campaign is intended to lift the spirits of the cancer community by sharing inspirational stories submitted by real people who are embracing their second chance at life. Through a mix of digital, social and traditional media, including billboards and print, TV, radio and online banner ads, the campaign encourages survivors to share how they’re loving life after cancer by submitting their stories and photos here.
African-American patient makes history; raises important discussion about minority participation in clinical trials
As the nation celebrates Black History Month in February, VCU Massey Cancer Center celebrates cancer patients who are making history. African-American Junius Hayes is one of them, helping medical researchers to pioneer new treatments for cancer. Hayes was the first patient in the United States to participate in a clinical trial to test a biodegradable balloon that, when inflated, would allow for more targeted radiation treatment of prostate cancer with less damage to the healthy areas surrounding the prostate.
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).